Myovant Sciences Profit Margin 2017-2022 | MYOV

Current and historical gross margin, operating margin and net profit margin for Myovant Sciences (MYOV) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Myovant Sciences net profit margin as of June 30, 2022 is -54.03%.
Myovant Sciences Annual Profit Margins
Myovant Sciences Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.444B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.052B 9.22
GSK (GSK) United Kingdom $62.454B 7.50
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.939B 16.64
Ginkgo Bioworks Holdings (DNA) United States $6.283B 0.00
Arcus Biosciences (RCUS) United States $1.941B 37.89
Emergent Biosolutions (EBS) United States $1.068B 6.19
ADC Therapeutics SA (ADCT) Switzerland $0.402B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.083B 0.00
SQZ Biotechnologies (SQZ) United States $0.073B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00
Biohaven Pharmaceutical Holding (BHVN) United States $0.000B 0.00